Shares of Viking Therapeutics, Inc. (NASDAQ: VKTX - Get Free Report) have earned a consensus recomme

The stock still presents a compelling case for investors, provided the clinical trial data can back

Viking Therapeutics (VKTX) reported earnings 30 days ago. What's next for the stock?

Investor sentiment on the key benefit of its lead drug candidate could be impacted in the current qu

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

Lilly's strong Q2, GLP-1 momentum and broad pipeline support growth, but valuation and rising compet

They are fairly risky, but their potential upside is massive.

JP Morgan analyst Hardik Parikh maintains Viking Therapeutics (NASDAQ:VKTX) with a Overweight and

Eli Lilly leads the GLP-1 market and could remain on top thanks to a deep pipeline. Viking Therapeut

Dimensional Fund Advisors LP boosted its stake in Viking Therapeutics, Inc. (NASDAQ: VKTX) by 18.0%

Viking Therapeutics (VKTX) maintains a Hold rating as competitive pressures intensify in the GLP-1 o

In a slow news month for the company, investors focused on the cost of its phase 3 trials rather tha

Viking Therapeutics beats second-quarter loss estimates as it advances late-stage obesity studies de

Viking Therapeutics Inc (NASDAQ:VKTX) shares are retreating Thursday despite reporting a narrower se

Canaccord Genuity analyst Edward Nash maintains Viking Therapeutics (NASDAQ:VKTX) with a Buy and

Viking Therapeutics, Inc. (VKTX) Q2 2026 Earnings Call Transcript

Viking Therapeutics NASDAQ: VKTX reported a wider second-quarter loss as the company increased spend

Viking Therapeutics (NASDAQ:VKTX) reported quarterly losses of $(1.10) per share which beat the anal

Conference call scheduled for 4:30 p.m. ET today -- Phase 3 VANQUISH 1 & 2 Trials for Subcutaneous V

Biotech is setting up as one of the more interesting risk-on trades heading into the back half of 20

Viking Therapeutics has a promising pipeline candidate in late-stage studies. Positive results from

Biotech earnings take center stage as Viking, Biogen, Bristol Myers, Regeneron and AbbVie prepare to

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations

Viking Therapeutics, Inc. (VKTX) reached $35.39 at the closing of the latest trading day, reflecting

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

Experienced Executive Brings Over Two Decades of Leadership Across Healthcare, Digital Health and Co

Viking Therapeutics (NASDAQ:VKTX) has outperformed the market over the past 10 years by 26.85% on an

A deepening chipmaker slide pulls all major U.S. indexes lower Tuesday while oil climbs on a Strait

Viking Therapeutics launches Phase 1 trial for obesity drug VK3019, a dual amylin/calcitonin recepto

Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical compa

A global semiconductor sell-off hammered the Nasdaq on Tuesday, but a rotation into defensives and s

Lake Street analyst Daniel Brims initiates coverage on Viking Therapeutics (NASDAQ:VKTX) with a B

Oral VK2735 demonstrated early, progressive weight loss from Week 1 through Week 13 without a platea

U.S. stocks sank Monday as an Iranian drone attack on a UAE petroleum site sent Brent above $114, go

Cantor Fitzgerald analyst Steve Seedhouse maintains Viking Therapeutics (NASDAQ:VKTX) with a Over

Viking Therapeutics (NASDAQ:VKTX) reported quarterly losses of $(1.37) per share which missed the an

HC Wainwright & Co. analyst Joseph Pantginis reiterates Viking Therapeutics (NASDAQ:VKTX) wit

U.S. equities fell broadly Wednesday as Brent Crude surged past $108 on reports of Iranian energy-fa

Viking shares rise after Novo's REDEFINE 4 trial trails Lilly's tirzepatide in weight loss.

Wall Street opened the week under heavy pressure as risk sentiment deteriorated on AI-related credit

Benzinga examined the prospects for many investors' favorite stocks over the last week — here&#3

Viking Therapeutics (NASDAQ:VKTX) stock is soaring on Thursday, extending the momentum it picked up